journal article
May 24, 2017
Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway
Topics
No keywords indexed for this article. Browse by subject →
References
39
[1]
O’Malley "Selective estrogen-receptor modulators and antihormonal resistance in breast cancer" J Clin Oncol (2007) 10.1200/jco.2007.11.3886
[2]
Itabashi "Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer" Breast Cancer Res Treat (2002) 10.1023/a:1013350419426
[3]
Cancer Genome Atlas Network "Comprehensive molecular portraits of human breast tumours" Nature (2012) 10.1038/nature11412
[4]
Barbareschi "mdm2 gene alterations and mdm2 protein expression in breast carcinomas" J Pathol (1995) 10.1002/path.1711750106
[5]
Cordon-Cardo "MDM2 and prognosis" Mol Cancer Res (2004) 10.1158/1541-7786.1.2.1
[6]
Wang "MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy" Curr Cancer Drug Targets (2005) 10.2174/1568009053332636
[7]
Gilks "MDM2 protein expression is a negative prognostic marker in breast carcinoma" Mod Pathol (2006) 10.1038/modpathol.3800484
[8]
Blaydes "p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells" Cancer Res (2003)
[9]
Levine "MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner" Cancer Res (2006) 10.1158/0008-5472.can-06-0180
[10]
Levine "A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells" Cancer Res (2007) 10.1158/0008-5472.can-06-2656
[11]
Bargonetti "A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation" Breast Cancer Res (2011) 10.1186/bcr2804
[12]
Hwang "A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans" Cell (2004) 10.1016/j.cell.2004.11.022
[13]
Das "Estrogen receptor alpha (ERalpha/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer" Oncotarget (2016) 10.18632/oncotarget.7533
[14]
Manfredi "p53-independent effects of Mdm2" Subcell Biochem (2014) 10.1007/978-94-017-9211-0_13
[15]
Eischen "Mdm2 affects genome stability independent of p53" Cancer Res (2009) 10.1158/0008-5472.can-08-3732
[16]
Wasylyk "p53-independent functions of MDM2" Mol Cancer Res (2003)
[17]
Bradley "Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis" Proc Natl Acad Sci U S A (1998) 10.1073/pnas.95.26.15608
[18]
Finlay "Targeted expression of Mdm2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53" Genes Dev (1997) 10.1101/gad.11.6.714
[19]
Kouzarides "Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein" Nature (1995) 10.1038/375691a0
[20]
Zhang "Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway" Oncogene (2005) 10.1038/sj.onc.1208814
[21]
Xiao "MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein" Mol Cell (2005) 10.1016/j.molcel.2005.10.017
[22]
Kitagawa "Mdm2-mediated pRB downregulation is involved in carcinogenesis in a p53-independent manner" Biochem Biophys Res Commun (2006) 10.1016/j.bbrc.2005.11.148
[23]
Kitagawa "Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation" EMBO J (2005) 10.1038/sj.emboj.7600486
[24]
Sutherland "Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2" J Biol Chem (1997) 10.1074/jbc.272.16.10882
[25]
Weisz "17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells" Oncogene (1996)
[26]
Zhang "Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy" Proc Natl Acad Sci U S A (2003) 10.1073/pnas.1934692100
[27]
Petersen "The organizing principle: microenvironmental influences in the normal and malignant breast" Differentiation (2002) 10.1046/j.1432-0436.2002.700907.x
[28]
Buck "Growth factor involvement in the multihormonal regulation of MCF-7 breast cancer cell growth in soft agar" Breast Cancer Res Treat (1991) 10.1007/bf01833356
[29]
Bargonetti "Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4" Proc Natl Acad Sci U S A (2015) 10.1073/pnas.1416318112
[30]
Bissell "The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression" Mol Oncol (2007) 10.1016/j.molonc.2007.02.004
[31]
Allis "Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation" Chromosoma (1997) 10.1007/s004120050256
[32]
Deb "The human oncoprotein MDM2 induces replication stress eliciting early intra-S-phase checkpoint response and inhibition of DNA replication origin firing" Nucleic Acids Res (2014) 10.1093/nar/gkt944
[33]
Hirshfield "Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs" Cancer Lett (2014) 10.1016/j.canlet.2014.04.009
[34]
Hayashi "MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells" Biochem Biophys Res Commun (2001) 10.1006/bbrc.2001.4339
[35]
Shaw "“Big Data” for breast cancer: where to look and what you will find" NPJ Breast Cancer (2016) 10.1038/npjbcancer.2016.31
[36]
Thomas "Effects of the pure anti-oestrogen ICI 182780 on oestrogen receptors, progesterone receptors and Ki67 antigen in human endometrium in vivo" Hum Reprod (1995) 10.1093/oxfordjournals.humrep.a135926
[37]
McDonnell "The turnover of estrogen receptor alpha by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy" Biochem Pharmacol (2011) 10.1016/j.bcp.2011.03.031
[38]
Ghosh "HAUSP, a novel deubiquitinase for Rb - MDM2 the critical regulator" FEBS J (2014) 10.1111/febs.12843
[39]
Kage "Breast cancer resistance to antiestrogens is enhanced by increased ER degradation and ERBB2 expression" Cancer Res (2017) 10.1158/0008-5472.can-16-1593
Metrics
26
Citations
39
References
Details
- Published
- May 24, 2017
- Vol/Issue
- 8(29)
- Pages
- 47916-47930
Authors
Cite This Article
Nandini Kundu, Angelika Brekman, Jun Yeob Kim, et al. (2017). Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway. Oncotarget, 8(29), 47916-47930. https://doi.org/10.18632/oncotarget.18147
Related
You May Also Like
Combination therapy in combating cancer
Reza Bayat Mokhtari, Tina S. Homayouni · 2017
2,188 citations
Circular RNA ITCH has inhibitory effect on ESCC by suppressing the Wnt/β-catenin pathway
Fang Li, Liyuan Zhang · 2015
530 citations
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
Kyle C. Strickland, Brooke E. Howitt · 2016
527 citations
Cold atmospheric plasma, a novel promising anti-cancer treatment modality
Dayun Yan, Jonathan H. Sherman · 2016
471 citations